Ravindra Gujar
MEI Pharma (United States)(US)
Publications by Year
Research Areas
Toxin Mechanisms and Immunotoxins, Microbial Inactivation Methods, RNA Interference and Gene Delivery, Cancer Research and Treatments, Immunotherapy and Immune Responses
Most-Cited Works
- → Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer(2019)251 cited
- → Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity(2019)65 cited
- → Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton’s Tyrosine Kinase and c-Src(2014)62 cited
- → S-allyl cysteine inhibits TNFα-induced skeletal muscle wasting through suppressing proteolysis and expression of inflammatory molecules(2017)34 cited
- → c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor(2016)16 cited
- → Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity(2022)15 cited
- → Efficient and modified protocol for zymography to detect muscle specific calpain activity(2017)9 cited
- → Runx proteins mediate protective immunity against Leishmania donovani infection by promoting CD40 expression on dendritic cells(2020)7 cited
- → Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes(2013)7 cited
- → Transforming growth factor-β1 impairs lymph node homing of dendritic cells by downregulating C-type lectin receptor-2 expression(2018)5 cited